Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05830110 · ClinicalTrials.gov registry record · NA
Patterned Multichannel Vibrotactile Stimulation for the Longitudinal Treatment of Moderate Stage Parkinson's Disease
A NA study of Parkinson's Disease, sponsored by Synergic Medical Technologies.
- Recruiting
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT05830110: Recruiting NA study of Parkinson's Disease, sponsored by Synergic Medical Technologies.
NCT05830110 is a NA study of Parkinson's Disease that is actively recruiting participants, run by Synergic Medical Technologies. The registered enrollment target is 30 participants, below the 635-participant average among 158 other Parkinson's Disease trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05830110, a NA study of Parkinson's Disease, is actively recruiting participants, sponsored by Synergic Medical Technologies.
- RECRUITING
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the present research is to examine the effectiveness of a non-invasive, vibrotactile stimulation protocol, known as coordinated reset (CR), for the alleviation of motor symptoms in patients with Parkinson's disease (PD). PD patients exhibit rigidity, slowness (bradykinesia) and poverty (akinesia) of movement as well as other symptoms. Treatment for PD is either pharmacological (first line) or invasive deep brain stimulation. The non-invasive, vibrotactile stimulation approach uses a novel stimulation pattern to disrupt the pathophysiological mechanism that is responsible for PD symptoms and thus restore motor function.
Primary Outcome
Change in MDS-UPDRS score using Part 3 of the scale.
Conditions Studied
Interventions
- DEVICE Sham vibrotactile coordinated reset
- DEVICE Active Vibrotactile Coordinated Reset
Study Locations (1)
Oregon
- Synergic Medical Technologies - Eugene
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2023-03-01 |
| Est. Completion | 2024-12 |
| Phase | NA |
What NCT05830110 shows while recruiting
NCT05830110 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 635-participant average among 158 other Parkinson's Disease trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Parkinson's Disease appearing as the primary indexed condition, and to 2 interventions - of which Sham vibrotactile coordinated reset is the first listed.
NCT05830110 reports a single indexed study location in Oregon.
Frequently Asked Questions
What is clinical trial NCT05830110 about?
NCT05830110 is a clinical study titled "Patterned Multichannel Vibrotactile Stimulation for the Longitudinal Treatment of Moderate Stage Parkinson's Disease". The purpose of the present research is to examine the effectiveness of a non-invasive, vibrotactile stimulation protocol, known as coordinated reset (CR), for the alleviation of motor symptoms in patients with Parkinson's disease (PD). PD patients exhibit rigidity, slowness (bradykinesia) and povert...
What is the current status of trial NCT05830110?
This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2023-03-01. Estimated completion is 2024-12.
What conditions does trial NCT05830110 study?
This clinical trial studies the following conditions: Parkinson's Disease.
What interventions are being tested in trial NCT05830110?
The interventions under investigation include: Sham vibrotactile coordinated reset (DEVICE), Active Vibrotactile Coordinated Reset (DEVICE).
Who is sponsoring clinical trial NCT05830110?
This trial is sponsored by Synergic Medical Technologies, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05830110 being conducted?
This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05830110's enrollment target sits among peer trials
30 108th of 158 higher than 47 of 158 other Parkinson's Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Parkinson's Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Novel DBS Stimulation Patterns for Treatment of Parkinson's Disease
RECRUITING · NA
-
Feasibility and Safety of a Portable Exoskeleton to Improve Mobility in Parkinson's Disease
RECRUITING · NA
-
Effects of Pallidal Deep Brain Stimulation Location on Motor Impairment in Parkinson's Disease
RECRUITING · NA
-
Remote Dynamic Cycling for the Customized Off-site Rehab in Parkinson's Disease
RECRUITING · NA
-
Deep Brain Stimulation Therapy in Movement Disorders
RECRUITING · NA
-
Combined STN and NBM Deep Brain Stimulation for Mild Cognitive Impairment in Parkinson's Disease
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI